[go: up one dir, main page]

PE20130603A1 - Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa - Google Patents

Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Info

Publication number
PE20130603A1
PE20130603A1 PE2013000161A PE2013000161A PE20130603A1 PE 20130603 A1 PE20130603 A1 PE 20130603A1 PE 2013000161 A PE2013000161 A PE 2013000161A PE 2013000161 A PE2013000161 A PE 2013000161A PE 20130603 A1 PE20130603 A1 PE 20130603A1
Authority
PE
Peru
Prior art keywords
liasa
pharmaceutical composition
composition containing
steroid inhibitor
steroid
Prior art date
Application number
PE2013000161A
Other languages
English (en)
Inventor
Masuo Yamaoka
Takahito Hara
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130603(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20130603A1 publication Critical patent/PE20130603A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE ESTEROIDE C17,20 LIASA TAL COMO (+)-6-(7-HIDROXI-6,7-DIHIDRO-5H-PIRROLO[1,2-c]IMIDAZOL-7-IL)-N-METIL-2-NAFTAMIDA; Y B) UN AGONISTA DEL RECEPTOR DE GnRH, UN ANTAGONISTA DEL RECEPTOR DE GnRH O UN FARMACO DE ADRENOCORTICOHORMONA TAL COMO ACETATO DE LEUPRORELINA O PREDNISOLONA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE CANCER DE PROSTATA INDEPENDIENTE DE ANDROGENOS
PE2013000161A 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa PE20130603A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007280813 2007-10-29

Publications (1)

Publication Number Publication Date
PE20130603A1 true PE20130603A1 (es) 2013-05-30

Family

ID=40591618

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013000161A PE20130603A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa
PE2008001841A PE20090931A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2008001841A PE20090931A1 (es) 2007-10-29 2008-10-28 Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Country Status (17)

Country Link
US (2) US20100261689A1 (es)
EP (1) EP2205239A2 (es)
JP (1) JP5430576B2 (es)
KR (1) KR20100088144A (es)
CN (1) CN101909622B (es)
AR (1) AR069079A1 (es)
AU (1) AU2008319767B8 (es)
CA (1) CA2703780A1 (es)
CL (1) CL2008003198A1 (es)
IL (1) IL205368A (es)
MX (1) MX2010004405A (es)
NZ (1) NZ585473A (es)
PE (2) PE20130603A1 (es)
RU (1) RU2481107C2 (es)
SG (1) SG185930A1 (es)
TW (1) TWI426901B (es)
WO (1) WO2009057795A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33740A (es) * 2010-11-18 2012-05-31 Takeda Pharmaceutical Método para tratar el cáncer de mama y cáncer de ovarios
WO2012158884A1 (en) * 2011-05-17 2012-11-22 Takeda Pharmaceutical Company Limited Pharmaceutical compositions and methods for treating cancer
US10201549B2 (en) 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710208B2 (en) * 1996-02-14 1999-09-16 Hoechst Marion Roussel, Inc. 17-beta-cyclopropyl(amino/oxy) 4-aza steroids as active inhibitors of testosterone 5-alpha-reductase and C17-20-lyase
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
AR034854A1 (es) * 2000-11-17 2004-03-24 Takeda Chemical Industries Ltd Compuesto de imidazol condensado, prodroga del mismo, composición farmaceutica y agente para reducir androgenos que lo contienen ,metodo para producirlo, sal diastereomerica de dicho compuesto y metodo para producir un compuesto opticamente activo del compuesto
CA2700690C (en) * 2002-01-10 2013-09-10 Takeda Pharmaceutical Company Limited Process for producing reformatsky reagent in stable form
CA2522784C (en) * 2003-04-01 2012-06-19 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
WO2004087190A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics Inc. Method for the treatment of prostate cancer
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
WO2006093353A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物
EP1861109A2 (en) * 2005-03-09 2007-12-05 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
CN101528308A (zh) * 2006-08-25 2009-09-09 库伽尔生物科技公司 治疗癌症的方法和组合物
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS

Also Published As

Publication number Publication date
US20100261689A1 (en) 2010-10-14
WO2009057795A2 (en) 2009-05-07
WO2009057795A3 (en) 2009-07-09
SG185930A1 (en) 2012-12-28
AR069079A1 (es) 2009-12-30
RU2481107C2 (ru) 2013-05-10
RU2010121765A (ru) 2011-12-10
CN101909622B (zh) 2013-06-19
AU2008319767A8 (en) 2014-01-09
AU2008319767B8 (en) 2014-01-09
TW200927097A (en) 2009-07-01
JP2011502114A (ja) 2011-01-20
AU2008319767A1 (en) 2009-05-07
CL2008003198A1 (es) 2009-12-18
JP5430576B2 (ja) 2014-03-05
MX2010004405A (es) 2010-05-03
NZ585473A (en) 2012-03-30
WO2009057795A8 (en) 2010-05-14
IL205368A0 (en) 2010-12-30
EP2205239A2 (en) 2010-07-14
AU2008319767B2 (en) 2013-12-19
TWI426901B (zh) 2014-02-21
CA2703780A1 (en) 2009-05-07
PE20090931A1 (es) 2009-08-03
IL205368A (en) 2014-08-31
KR20100088144A (ko) 2010-08-06
US20140256693A1 (en) 2014-09-11
AU2008319767A2 (en) 2010-06-17
CN101909622A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
BRPI0809931B8 (pt) antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
UA107782C2 (ru) Антагонисты рецепторов fgf-r4
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
PH12013500481A1 (en) Estrogen receptor modulators and uses thereof
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
EP2395834A4 (en) Sodium nitrite-containing pharmaceutical compositions
PE20150644A1 (es) Metodos y composiciones para determinar la resistencia a la terapia con receptor de androgeno
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
CR10748A (es) Compuesto de indol
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
CL2010001624A1 (es) Uso de compuestos derivados de bisfenol diglicidil para tratar el cancer de prostata; compuestos derivados de bisfenol diglicidil eter; y composicion farmaceutica que compprende el compuesto.
NZ608673A (en) Therapeutic use of a tlr agonist and combination therapy
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
MX2009009429A (es) Analogos de ciclopamina lactama y metodos de uso de los mismos.
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
NI201300043A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
CL2015002202A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4.

Legal Events

Date Code Title Description
FD Application declared void or lapsed